Optimization of the experimental conditions for determination of roxithromycin in bulk and dosage forms

  • Received : 2017.01.25
  • Accepted : 2017.02.12
  • Published : 2017.02.25


Roxithromycin (RXT), which is an antibiotic used to treat respiratory tract and urinary infections, is official in Korean Pharmacopoeia (KP) and is marketed in various dosage forms including tablet, granule, suspension, and tablet for suspension in Korea. This study presents how a universal and reliable method to quantify RXT in bulk drug and formulations was developed. Effects of factors including column type, buffer concentration, type and concentration of organic solvent, buffer pH, and type and concentration of mobile phase additive, were examined, and some categorical or crucial factors including the types of column, organic solvent, mobile phase additive and the buffer pH were optimized by one-factor-at-a-time approach. Subsequently, concentrations of the buffer and additive and column temperature were optimized by response surface methodology using Box-Behnken design aiming to acquire the RXT peak of good shape. The optimized method employed a Phenomenex Gemini $5{\mu}$ C18 110A ($150{\times}4.60mm$, $5{\mu}m$) maintained at $30^{\circ}C$ with the mobile phase consisting of 25 mM phosphate buffer (pH 6.0) with 0.3 % tetrabutylammonium hydroxide and methanol at a ratio of 37:63 (v/v). Method validation results showed that the developed method was linear, precise, and accurate. Compared to the compendial methods in KP 10 that exhibited a significant tailing of the RXT peak despite using unfavorably high buffer concentrations and were not harmonized among bulk drug and formulations, this method could be universally applied to RXT bulk drug and marketed products in various dosage forms and thus was adopted in KP 11.


Supported by : Ministry of Food and Drug Safety


  1. D. G. Kennedy, R. J. McCracken, A. Cannavan, and S. A. Hewitt, J.Chromatogr. A, 812(1-2), 77-98 (1998).
  2. A. D. Russell, 152-186 (2004).
  3. J. Macek, P. Ptacek, and J. Klima, J. Chromatogr. B, 723(1-2), 233-238 (1999).
  4. M. Wahba, J. Chromatogr. Sci., 51(1), 44-52 (2013).
  5. H. Chepkwony, F. Kamau, E. Rodriguez, E. Roets, and J. Hoogmartens, Chromatographia, 54(11-12), 725-729 (2001).
  6. V. de Oliveira, A. M. Bergold, and E. E. S. Schapoval, Analytical Letters, 29(13), 2377-2382 (1996).
  7. J. S. Torano and H.-J. Guchelaar, J. Chromatogr. B, 720(1), 89-97 (1998).
  8. A. Pappa-Louisi, A. Papageorgiou, A. Zitrou, S. Sotiropoulos, E. Georgarakis, and F. Zougrou, J. Chromatogr. B, 755(1), 57-64 (2001).
  9. C. Taninaka, H. Ohtani, E. Hanada, H. Kotaki, H. Sato, and T. Iga, J. Chromatogr. B, 738(2), 405-411(2000).
  10. N. Grgurinovich and A. Matthews, J. Chromatogr. B, 433, 298-304 (1988).
  11. J.-H. Lim, B.-S. Jang, R.-K. Lee, S.-C. Park, and H.-I. Yun, J. Chromatogr. B, 746(2), 219-225 (2000).
  12. P. Wang, M. Qi, and X. Jin, J. Pharm. Biomed. Anal., 39(3), 618-623 (2005).
  13. P. S. B. Drug Evaluation Department, Korean Food & Drug Administration (KFDA), 'Guideline of Validation of Analytical Procedures for Pharmaceuticals', 1-23, (September, 2012).
  14. S. Şanli, İ. M. Palabiyik, N. Şanli, Z. B. Guzel-Seydim, and G. Alsancak, J. Anal. Chem., 66(9), 838 (2011).
  15. J. Macek, P. Ptacek, and J. Klima, J. Chromatogr. B, 723(1), 233-238 (1999).
  16. K. M. Jeong, J. Zhao, Y. Jin, S. R. Heo, S. Y. Han, D. E. Yoo, and J. Lee, Arch. Pharm. Res., 38(12), 2143-2152 (2015).